Cargando…

Variability in detection and quantification of interferon β-1b–induced neutralizing antibodies

BACKGROUND: Interferon-beta (IFNB) therapy for multiple sclerosis can lead to the induction of neutralizing antibodies (NAbs) against IFNB. Various methods are used for detection and quantification of NAbs. METHODS: Blood samples from 125 IFNB-1b–treated patients, which were tested NAb negative or N...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hartung, Hans-Peter, Kieseier, Bernd, Goodin, Douglas S, Arnason, Barry GW, Comi, Giancarlo, Cook, Stuart, Filippi, Massimo, Jeffery, Douglas R, Kappos, Ludwig, Bogumil, Timon, Stemper, Brigitte, Sandbrink, Rupert, Nakada, Yukiko, Nakajima, Haruhiko, Schwenke, Susanne, Lehr, Stephan, Heubach, Jürgen, Pohl, Christoph, Reischl, Joachim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403940/ https://www.ncbi.nlm.nih.gov/pubmed/22703536 http://dx.doi.org/10.1186/1742-2094-9-129

Ejemplares similares

Predictors of disease activity in 857 patients with MS treated with interferon beta-1b
por: Hartung, Hans-Peter, et al.
Publicado: (2015)

Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial
por: Schippling, Sven, et al.
Publicado: (2016)

Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis
por: Penner, Iris-Katharina, et al.
Publicado: (2012)

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
por: Edan, G, et al.
Publicado: (2014)

Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis
por: Freedman, MS, et al.
Publicado: (2012)

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial
por: Kappos, Ludwig, et al.
Publicado: (2016)

Molecular mechanism underlying the impact of vitamin D on disease activity of MS
por: Munger, Kassandra L, et al.
Publicado: (2014)

MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome
por: Nielsen, Jessica M, et al.
Publicado: (2009)

Correction: Prognostic implications of a carefully performed neurological assessment in patients with a first event suggestive of multiple sclerosis
por: Nielsen, Jessica M, et al.
Publicado: (2011)

The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis
por: Rocca, Maria A., et al.
Publicado: (2017)

Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis
por: van den Elskamp, I. J., et al.
Publicado: (2010)

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study
por: Cohen, Jeffrey A, et al.
Publicado: (2018)

The Causal Cascade to Multiple Sclerosis: A Model for MS Pathogenesis
por: Goodin, Douglas S.
Publicado: (2009)

The genetic basis of multiple sclerosis: a model for MS susceptibility
por: Goodin, Douglas S
Publicado: (2010)

The Genetic and Environmental Bases of Complex Human-Disease: Extending the Utility of Twin-Studies
por: Goodin, Douglas S.
Publicado: (2012)

The nature of genetic susceptibility to multiple sclerosis: constraining the possibilities
por: Goodin, Douglas S.
Publicado: (2016)

Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials
por: Harris, Sarah, et al.
Publicado: (2021)

New immunopathologic insights into multiple sclerosis
por: Hemmer, Bernhard, et al.
Publicado: (2003)

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
por: Cohen, Jeffrey A, et al.
Publicado: (2016)

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial
por: Cree, Bruce AC, et al.
Publicado: (2022)

Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study
por: Freedman, Mark S., et al.
Publicado: (2014)

Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes
por: De Stefano, Nicola, et al.
Publicado: (2014)

Immunomodulatory potential of anti-IFN-beta antibodies on monocyte-derived macrophages
por: Sominanda, Ajith, et al.
Publicado: (2023)

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a
por: Havrdová, Eva, et al.
Publicado: (2018)

Single Nucleotide Polymorphism (SNP)-Strings: An Alternative Method for Assessing Genetic Associations
por: Goodin, Douglas S., et al.
Publicado: (2014)

Benefit–Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis
por: Comi, Giancarlo, et al.
Publicado: (2017)

A comparative analysis of Patient-Reported Expanded Disability Status Scale tools
por: Collins, Christian DE, et al.
Publicado: (2015)

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine
por: Warnke, Clemens, et al.
Publicado: (2010)

Combinatorics of compositions and words
por: Heubach, Silvia, et al.
Publicado: (2009)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

Review of teriflunomide and its potential in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2009)

Leukocyte Counts and Ratios Are Predictive of Stroke Outcome and Hemorrhagic Complications Independently of Infections
por: Semerano, Aurora, et al.
Publicado: (2020)

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study
por: Gold, Ralf, et al.
Publicado: (2013)

Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
por: Centonze, Diego, et al.
Publicado: (2021)

MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study
por: Fox, Robert J., et al.
Publicado: (2014)

The Brain Functional Networks Associated to Human and Animal Suffering Differ among Omnivores, Vegetarians and Vegans
por: Filippi, Massimo, et al.
Publicado: (2010)

Climate Change is Likely to Worsen the Public Health Threat of Diarrheal Disease in Botswana
por: Alexander, Kathleen A., et al.
Publicado: (2013)

Haplotype-based approach to known MS-associated regions increases the amount of explained risk
por: Khankhanian, Pouya, et al.
Publicado: (2015)

Highly conserved extended haplotypes of the major histocompatibility complex and their relationship to multiple sclerosis susceptibility
por: Goodin, Douglas S., et al.
Publicado: (2018)

The nature of genetic and environmental susceptibility to multiple sclerosis
por: Goodin, Douglas S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9vvs43novnhl5bnsuf7helrsg3